June 11, 2026: Sudarshan Pharma US subsidiary has become a reality as Sudarshan Pharma Industries Limited announced the incorporation of Sudarshan Industries Inc. (Sudarshan USA) as a wholly-owned subsidiary in the United States. The company informed stock exchanges that the new entity was incorporated on June 5, 2026, in Delaware, USA.

 

Author: Aadarsh Patel | EQMint

 

The move marks a significant step in Sudarshan Pharma’s international growth strategy and is aimed at strengthening its presence in one of the world’s largest pharmaceutical markets.

 

Key details of Sudarshan USA

According to the filing, Sudarshan Pharma has subscribed to 1,00,00,000 shares of Sudarshan USA at a face value of US$0.00001 per share, aggregating to US$100 (approximately ₹9,600), giving it 100% ownership of the subsidiary.

 

The subsidiary will engage in:

 

• • pharmaceuticals

• • active pharmaceutical ingredients (APIs)

• • nutraceuticals

• • healthcare products

• • dietary supplements

• • vaccines

• • specialty chemicals

• • pharmaceutical intermediates

Why the company is setting up a US subsidiary

The company stated that Sudarshan USA will enable it to enlarge its customer base in the United States, helping strengthen international business opportunities and market access.

 

The incorporation does not qualify as a related-party transaction, and the investment will be made through cash subscription after obtaining necessary approvals under RBI’s overseas investment regulations.

 

Management update

The filing also disclosed that Mr. Sachin Mehta, Joint Managing Director, has been appointed as the first director of Sudarshan USA.

 

EQMint Analysis on Sudarshan Pharma US subsidiar

The establishment of Sudarshan Pharma US subsidiary is a strategically positive development for the company. Direct presence in the US market can potentially improve customer acquisition, strengthen distribution networks and support exports of pharmaceutical and healthcare products.

 

While the financial investment involved is currently small, the long-term significance lies in creating a platform for future expansion in the highly regulated but lucrative US pharmaceutical market. Investors will now watch how effectively Sudarshan Pharma leverages this subsidiary to generate new business opportunities and international revenue growth.

 

For more such information visit EQMint

 

Join our Whatsapp channel for timely updates: Whatsapp

 

Disclaimer:  This article is not an investment advice and is for educational purpose only.